ImmunityBio (NASDAQ:IBRX) Shares Up 15.2% – What’s Next?

ImmunityBio, Inc. (NASDAQ:IBRX) shares shot up 15.2% during trading on Tuesday . The stock traded as high as $7.76 and last traded at $7.67. 23,811,974 shares traded hands during mid-day trading, a decline of 39% from the average session volume of 39,122,590 shares. The stock had previously closed at $6.66.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio announced $75 million of non‑dilutive financing (part of $100M in financing transactions) under an amended Royalty Interest Purchase Agreement, increasing committed capital and extending the company’s runway to support commercialization and pipeline work. This reduces immediate dilution risk and is a clear near‑term liquidity positive. ImmunityBio Strengthens Balance Sheet (BusinessWire)
• Positive Sentiment: Market coverage picked up after the financing: headlines note the financing as the proximate reason shares are rising, helping explain today’s move. Watch for follow‑on analyst comments. Why Are ImmunityBio Shares Rising Today? (Benzinga)
• Positive Sentiment: TV/reactive market commentary: Jim Cramer said he would encourage owning IBRX as a speculative position, which can draw retail buying and intraday momentum. Such media endorsements often amplify volatility in small/volatile biotech names. Jim Cramer on ImmunityBio (MSN)
• Negative Sentiment: The FDA sent a warning letter over promotional claims relating to ImmunityBio’s lead biologic (Anktiva), citing misleading efficacy statements; that regulatory action triggered significant prior share weakness and elevates clinical/regulatory risk and reputational damage. This remains the primary fundamental overhang. ImmunityBio Receives FDA Warning Letter (Yahoo Finance)
• Negative Sentiment: Multiple securities class actions and investor‑rights firm notices have been filed or announced (covering purchases between Jan 19, 2026 and Mar 24, 2026) and several firms are soliciting lead‑plaintiff applications; litigation risk and potential financial exposure (legal costs, settlements) create a material overhang. Investor Alert — Robbins Geller (PR Newswire)
• Negative Sentiment: Separately, a number of law firms have opened investigations and filed complaints (including Hagens Berman, Rosen, Glancy, KSF, Faruqi and others), increasing the probability of consolidated litigation and drawing more media/regulatory attention. This prolongs uncertainty for investors. Hagens Berman Class Action Notice (PR Newswire)

Analyst Ratings Changes

IBRX has been the subject of several research analyst reports. BTIG Research began coverage on ImmunityBio in a research note on Thursday, March 12th. They set a “buy” rating and a $13.00 target price for the company. The Goldman Sachs Group reissued a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. Jefferies Financial Group upped their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. HC Wainwright increased their price objective on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Finally, D. Boral Capital reiterated a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a research report on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, ImmunityBio currently has a consensus rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Stock Up 15.2%

The firm has a market cap of $7.89 billion, a PE ratio of -20.18 and a beta of -0.04. The firm has a 50-day moving average price of $7.70 and a two-hundred day moving average price of $4.27.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million during the quarter. Research analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at ImmunityBio

In other news, Director Christobel Selecky sold 25,000 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Barry J. Simon sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total transaction of $900,750.00. Following the completion of the transaction, the director directly owned 2,850,821 shares in the company, valued at approximately $34,238,360.21. This represents a 2.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 501,967 shares of company stock worth $4,466,412. 69.48% of the stock is currently owned by corporate insiders.

Institutional Trading of ImmunityBio

A number of hedge funds have recently bought and sold shares of IBRX. Slow Capital Inc. acquired a new position in shares of ImmunityBio during the 3rd quarter worth approximately $25,000. Truist Financial Corp purchased a new stake in shares of ImmunityBio in the third quarter valued at approximately $27,000. Swiss Life Asset Management Ltd acquired a new stake in shares of ImmunityBio in the third quarter valued at approximately $27,000. WealthPlan Investment Management LLC acquired a new stake in shares of ImmunityBio in the fourth quarter valued at approximately $27,000. Finally, Diversify Advisory Services LLC purchased a new position in ImmunityBio during the second quarter worth approximately $27,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.